Regulators Want Tough Criteria For COVID-19 Vaccine Efficacy Trials
Standardized Endpoints Needed In Phase III Studies
Executive Summary
The International Coalition of Medicines Regulatory Authorities have sketched out the criteria that should be met before candidate coronavirus vaccines can proceed into late-stage trials, and agreed on how to design the studies and who should be included.
You may also be interested in...
EU Eases GMO Rules To Speed Trials Of COVID-19 Vaccines
The need to accelerate clinical trials of products for treating and preventing coronavirus has led the EU authorities to propose a more streamlined process for allowing the release of GMO-containing investigational medicinal products into the environment.
Coronavirus Update: Big Trials, New Vaccine Platforms, And Fake Chloroquine In Africa
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national and EU level.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.